Historical Data SIG

Objectives

Many approaches for designing and analyzing clinical trials using historical (or other external study) data have been proposed in the recent past. For example, proposals have been made for bridging studies, the combination of randomized and non-randomized evidence, and also for more general problems such as across-phases probability of success calculations. In addition, the ever-increasing number of patient registries and databases for routinely collected data, and recent data sharing initiatives (e.g., TransCelerate), further underline the importance of these approaches. However, there are still many open questions concerning the role which clinical trials that use such data can have in drug development. In our opinion, the three most important questions are:

  • What is the state of the art regarding approaches to incorporate historical data into the formal design and analysis of clinical trials?
  • Which statistical methods should we use to make historical and current data comparable?
  • What are the regulatory requirements necessary for the acceptance of historical data in drug approval?

The scope of this SIG is to provide some answers to the above questions through a variety of activities. These will include:

  • Publishing reviews of the available methods, sources of historical data and case studies.
  • Collaborating with experts to refine and possibly extend the available methods.
  • Interacting with regulators to obtain a better understanding of their requirements.
  • Providing trainings, workshops and talks.
  • Promoting good practice through templates for study protocols and statistical analysis plans.


Who we are

Name Company/Institution
Nicky Best (co-lead)
 GSK
Simon Wandel (co-lead)  Novartis
Byron Jones (Chair)  Novartis
Lisa Hampson
 Novartis
Sebastian Weber  Novartis
Frank Fleischer  Boehringer Ingelheim
Nelson Kinnersley  Roche
David Dejardin
 Roche
Ros Walley  UCB
Adrian Mander  MRC Cambridge
Graeme Archer  GSK



How to get in touch


Contact:
Byron Jones (Novartis)
Email: byron.jones@novartis.com



Latest News

Coming soon...



Upcoming Events

Coming soon...

Latest News


Show all news

EventsFuture Events


  • Webinar: MCP-Mod – Theory, Implementation and Extensions - Dates: 08 – 08 May, 2019

    MCP-Mod (Multiple Comparisons & Modelling) is a popular statistical methodology for model-based design and analysis of dose finding studies. This webinar will describe the theory behind MCP-Mod (plus extensions), and how to implement it within available software. Pantelis Vlachos (Cytel) will provide a brief introduction to the methodology and illustrate the MCP-MoD capabilities in EAST 6.5. Saswati Saha (University of Brehem) will discuss new variations and alternatives to MCP-Mod and show how to implement them in R. Neal Thomas (Pfizer) will present further technical details of MCP-Mod by evaluating the method using results from least squares linear model theory.
  • PSI Toxicology SIG Workshop 2019 - Dates: 02 – 03 Apr, 2019

    This 1.5-day workshop will involve approximately 20 statisticians, focusing on discussions around “best practice” in the statistical analysis of various data types.​